A new version of Sanofi Pasteur MSD’s Gardasil has been approved by European regulators for protection against nine strains of the human papillomavirus, covering more types than any other HPV vaccine on the market. 

Gardasil 9 has been cleared for active immunisation of both females and males from the age of nine against premalignant lesions and cancers affecting the cervix, vulva, vagina or anus and also against genital warts caused by the 9 HPV types covered by the vaccine.

The seven high-risk HPV types in Gardasil 9 cause around 90% of cervical cancer, 90% of HPV related anal cancer and 80% of high-grade cervical lesions worldwide, while the two lower-risk types, HPV 6 and 11, are responsible for around 90% of genital wart cases, the firm noted.

For more details, go to: http://www.pharmatimes.com/Article/15-06-17/EU_approves_Sanofi_s_new_Gardasil_jab.aspx